Scarica l'app Stockscreener
1.42
7.19%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.53
Aprire:
$1.56
Volume 24 ore:
8.67M
Relative Volume:
1.29
Capitalizzazione di mercato:
$426.53M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-0.9467
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-4.70%
1M Prestazione:
+16.39%
6M Prestazione:
+2.90%
1 anno Prestazione:
-8.39%
Intervallo 1D:
$1.3735
$1.56
Intervallo di 1 settimana:
$1.3735
$1.595
Portata 52W:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.42 | 459.57M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Can Pacific Biosciences of California Inc. stock resist market sell offsWeekly Trade Review & High Win Rate Trade Alerts - newser.com
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - TradingView
Weiss Ratings Reiterates Sell (E+) Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Detecting price anomalies in Pacific Biosciences of California Inc. with AIEarnings Risk Report & Daily Growth Stock Tips - newser.com
What analysts say about Pacific Biosciences of California Inc P09 stockHealthcare Stock Analysis & Rapid Profit Growth - earlytimes.in
How HiFi sequencing achieves scalable microbial genomics without compromise - PacBio
Forecasting Pacific Biosciences of California Inc. price range with options dataWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosIndex Update & Stock Portfolio Risk Management - newser.com
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell - MSN
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Technology Chosen for Major Longevity Study - GuruFocus
7,800 Genomes & Epigenomes: PacBio Powers Long Life Family Study with Revio, Q4 2025 Start - Stock Titan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
PacBio Expands Partnership with seqWell to Distribute LongPlex™ Multiplexing Kit for Enhanced Genomic Sequencing Solutions - Quiver Quantitative
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs - Yahoo Finance
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - sharewise.com
Is Pacific Biosciences of California Inc. (P09) stock a buy before new product rollout2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Will Pacific Biosciences of California Inc. stock outperform Nasdaq indexJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Pacific Biosciences of California Inc. stock is rated strong buy2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Is this a good reentry point in Pacific Biosciences of California Inc.July 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Will Pacific Biosciences of California Inc. rebound enough to break evenJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
Is Pacific Biosciences of California Inc. a candidate for recovery playJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Heatmap analysis for Pacific Biosciences of California Inc. and competitorsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5 - 富途牛牛
Can volume confirm reversal in Pacific Biosciences of California Inc.Portfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Can swing trading help recover from Pacific Biosciences of California Inc. losses2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Powered by PacBio: Selected publications from September 2025 - PacBio
Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
PacBio Enters Carrier Screening Market With PureTarget Expansion - sharewise.com
What drives Pacific Biosciences of California Inc P09 stock priceGlobal Market Influence & Outstanding Investment Returns - earlytimes.in
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Best data tools to analyze Pacific Biosciences of California Inc. stockJuly 2025 Decliners & Verified Short-Term Plans - newser.com
Pacbio’s Puretarget simplifies carrier screening - BioWorld MedTech
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):